CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation

OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect therapeutic outcome during treatment. The distribution of variant CYP2C9 alleles and prevalence of phenytoin adverse reactions were hereby investigated in a population of patients diagnosed with epilepsy. METHOD: Allele-specific PCR analysis was carried out in order to determine frequencies of the two most common variant alleles, CYP2C9*2 and CYP2C9*3 in genomic DNA isolated from 100 epileptic patients. We also analyzed the frequency of phenytoin adverse reactions among those different genotypes groups. The data was presented as mean±standard deviation. RESULTS: The mean age at enrollment was 39.6±10.3 years (range, 17-72 years) and duration of epilepsy was 26.5±11.9 years (range 3-48 years). The mean age at epilepsy onset was 13.1±12.4 years (range, 1 month-62 years). Frequencies of CYP2C9*1 (84%), CYP2C9*2 (9%) and CYP2C9*3 (7%) were similar to other published reports. Phenytoin adverse reactions were usually mild and occurred in 15% patients, without correlation with the CYP2C9 polymorphism (p=0.34). CONCLUSION: Our findings indicate an overall similar distribution of the CYP2C9 alleles in a population of patients diagnosed with epilepsy in the South of Brazil, compared to other samples. This sample of phenytoin users showed no drug related adverse reactions and CYP2C9 allele type correlation. The role of CYP2C9 polymorphism influence on phenytoin adverse reaction remains to be determined since some literature evidence and our data found negative results.

Saved in:
Bibliographic Details
Main Authors: Twardowschy,Carlos Alexandre, Werneck,Lineu César, Scola,Rosana Herminia, Paola,Luciano De, Silvado,Carlos Eduardo
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200002
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2011000200002
record_format ojs
spelling oai:scielo:S0004-282X20110002000022011-04-26CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlationTwardowschy,Carlos AlexandreWerneck,Lineu CésarScola,Rosana HerminiaPaola,Luciano DeSilvado,Carlos Eduardo CYP2C9 polymorphism Brazilian population phenytoin adverse reactions OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect therapeutic outcome during treatment. The distribution of variant CYP2C9 alleles and prevalence of phenytoin adverse reactions were hereby investigated in a population of patients diagnosed with epilepsy. METHOD: Allele-specific PCR analysis was carried out in order to determine frequencies of the two most common variant alleles, CYP2C9*2 and CYP2C9*3 in genomic DNA isolated from 100 epileptic patients. We also analyzed the frequency of phenytoin adverse reactions among those different genotypes groups. The data was presented as mean±standard deviation. RESULTS: The mean age at enrollment was 39.6±10.3 years (range, 17-72 years) and duration of epilepsy was 26.5±11.9 years (range 3-48 years). The mean age at epilepsy onset was 13.1±12.4 years (range, 1 month-62 years). Frequencies of CYP2C9*1 (84%), CYP2C9*2 (9%) and CYP2C9*3 (7%) were similar to other published reports. Phenytoin adverse reactions were usually mild and occurred in 15% patients, without correlation with the CYP2C9 polymorphism (p=0.34). CONCLUSION: Our findings indicate an overall similar distribution of the CYP2C9 alleles in a population of patients diagnosed with epilepsy in the South of Brazil, compared to other samples. This sample of phenytoin users showed no drug related adverse reactions and CYP2C9 allele type correlation. The role of CYP2C9 polymorphism influence on phenytoin adverse reaction remains to be determined since some literature evidence and our data found negative results.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.69 n.2a 20112011-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200002en10.1590/S0004-282X2011000200002
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Twardowschy,Carlos Alexandre
Werneck,Lineu César
Scola,Rosana Herminia
Paola,Luciano De
Silvado,Carlos Eduardo
spellingShingle Twardowschy,Carlos Alexandre
Werneck,Lineu César
Scola,Rosana Herminia
Paola,Luciano De
Silvado,Carlos Eduardo
CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
author_facet Twardowschy,Carlos Alexandre
Werneck,Lineu César
Scola,Rosana Herminia
Paola,Luciano De
Silvado,Carlos Eduardo
author_sort Twardowschy,Carlos Alexandre
title CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
title_short CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
title_full CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
title_fullStr CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
title_full_unstemmed CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
title_sort cyp2c9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation
description OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect therapeutic outcome during treatment. The distribution of variant CYP2C9 alleles and prevalence of phenytoin adverse reactions were hereby investigated in a population of patients diagnosed with epilepsy. METHOD: Allele-specific PCR analysis was carried out in order to determine frequencies of the two most common variant alleles, CYP2C9*2 and CYP2C9*3 in genomic DNA isolated from 100 epileptic patients. We also analyzed the frequency of phenytoin adverse reactions among those different genotypes groups. The data was presented as mean±standard deviation. RESULTS: The mean age at enrollment was 39.6±10.3 years (range, 17-72 years) and duration of epilepsy was 26.5±11.9 years (range 3-48 years). The mean age at epilepsy onset was 13.1±12.4 years (range, 1 month-62 years). Frequencies of CYP2C9*1 (84%), CYP2C9*2 (9%) and CYP2C9*3 (7%) were similar to other published reports. Phenytoin adverse reactions were usually mild and occurred in 15% patients, without correlation with the CYP2C9 polymorphism (p=0.34). CONCLUSION: Our findings indicate an overall similar distribution of the CYP2C9 alleles in a population of patients diagnosed with epilepsy in the South of Brazil, compared to other samples. This sample of phenytoin users showed no drug related adverse reactions and CYP2C9 allele type correlation. The role of CYP2C9 polymorphism influence on phenytoin adverse reaction remains to be determined since some literature evidence and our data found negative results.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200002
work_keys_str_mv AT twardowschycarlosalexandre cyp2c9polymorphisminpatientswithepilepsygenotypicfrequencyanalyzesandphenytoinadversereactionscorrelation
AT wernecklineucesar cyp2c9polymorphisminpatientswithepilepsygenotypicfrequencyanalyzesandphenytoinadversereactionscorrelation
AT scolarosanaherminia cyp2c9polymorphisminpatientswithepilepsygenotypicfrequencyanalyzesandphenytoinadversereactionscorrelation
AT paolalucianode cyp2c9polymorphisminpatientswithepilepsygenotypicfrequencyanalyzesandphenytoinadversereactionscorrelation
AT silvadocarloseduardo cyp2c9polymorphisminpatientswithepilepsygenotypicfrequencyanalyzesandphenytoinadversereactionscorrelation
_version_ 1756374506431053824